This study covers historical growth trajectory and major growth drivers and restraints in order to come up with a reliable projection for the market’s likely growth trajectory over the forecast period from 2018 to 2023.
Pune, India – February 12, 2019 —
Precision medicine refers to medicines developed as per an individual’s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases. The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2022.
The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/925
The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.
Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.
Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine
The global precision medicine market is expected to reach USD 88.64 billion by 2022.
By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2022.
By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2022.
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.
Browse Complete 313 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/precision-medicine-market-925
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Contact Us:, https://www.marketresearchfuture.com, Office No. 528, Amanora Chambers, Magarpatta Road, Hadapsar,, Pune – 411028, Maharashtra, India, Phone: +1 646 845 9312, Email: email@example.com
Phone: +1 646 845 9312
This content is not produced by Reuters Editorial News. It is produced by VC NewsNetwork. For content enquiry, please reach us at
Proceedings will go into building the team, focus on community engagement, and marketing efforts.
The firm currently focuses investing on Indonesian based companies only.
MIT proposes a private placement of 90.44 million new units to raise a minimum gross proceeds of S$175 million (about US$129 million).
The funding is led by its parent group Frontier Car Group and joined by Toyota Tunas Indonesia.
LOGIVAN plans to implement artificial intelligence to improve its data analysis and cross-platform integration.